Article

Oncology on Canvas Winner's Cancer Experience Shapes Her Artwork

Susan Hope Schaffer, the 2014 Oncology on Canvas overall winner, shares how her experience with breast cancer helped her evolve as an artist.

Susan Hope Schaffer, this year's Oncology on Canvas overall winner, shares how her experience with breast cancer has helped her evolve as an artist. Her piece, "Visions of Hope," highlights how her medical team, family and other cancer survivors gave her hope through diagnosis and treatment.

"My cancer journey has gone from some pain and anguish to a beautiful result, and that's the artwork that I've created," she says. Schaffer wants her artwork, which she has submitted to the Oncology on Canvas art competition since 2008, to give hope and energy to others going through cancer.

Schaffer, who is from Bethlehem, Pa., said the competition has given her a voice over the years to document her journey, including appreciation, fear and anger. This year's piece, she says, shows the hope she's gained from her cancer experience. "Visions of Hope," along with hundreds of other submissions to this year's competition, will be on display throughout the United States in a traveling art exhibit beginning in early 2015.

[Watch "Oncology on Canvas and The Hope Murals Project Reaches New York City"]

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
a man and a woman in front of a dark blue background
a man and a woman in front of a dark blue background
Related Content